Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer

A Phase III study testing Keytruda monotherapy in second-line esophageal cancer versus physician’s choice of chemotherapy shows a 31% reduction in risk of death for patients expressing PD-L1. [Editor's Note: Article updated to clarify trial outcomes.]